Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96D09
UPID:
GASP2_HUMAN
Alternative names:
-
Alternative UPACC:
Q96D09; D3DXA0; Q8NAB4
Background:
G-protein coupled receptor-associated sorting protein 2 plays a crucial role in the regulation of G-protein coupled receptors (GPCRs), which are key in cellular communication and signal transduction. Its involvement in the intricate processes that govern cellular responses makes it a focal point of research.
Therapeutic significance:
The protein is linked to Deafness, X-linked, 7, a congenital disorder characterized by bilateral mixed or conductive hearing loss, which may progress in some patients. This association highlights its potential as a target for therapeutic intervention in hearing loss and related dysmorphisms.